Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Quick facts
Marketed products
- olmesartan/amlodipine + hydrochlorothiazide, if necessary. · Cardiovascular
This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways. - olmesartan medoxomil + hydrochlorothiazide, if necessary · Cardiovascular
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. - Olmesartan medoxomil tablets low dose · Cardiovascular
Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. - Perindopril + amlodipine + if necessary, hydrochlorothiazide · Cardiovascular
This combination reduces blood pressure by blocking angiotensin II formation (perindopril), relaxing blood vessel smooth muscle (amlodipine), and reducing fluid volume (hydrochlorothiazide).
Phase 3 pipeline
- losartan + hydrochlorothiazide, if necessary · Cardiovascular
Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure. - nitrendipine + hydrochlorothiazide, if necessary
- Olmesartan medoxomil tablets high dose · Cardiovascular
Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. - VKA-Based Regimen · Cardiovascular
VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company portfolio CI brief
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company pipeline updates RSS
Frequently asked questions about Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
What are Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company's marketed drugs?
Top marketed products include olmesartan/amlodipine + hydrochlorothiazide, if necessary., olmesartan medoxomil + hydrochlorothiazide, if necessary, Olmesartan medoxomil tablets low dose, Perindopril + amlodipine + if necessary, hydrochlorothiazide.
What is Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company's pipeline?
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company has 4 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include losartan + hydrochlorothiazide, if necessary, nitrendipine + hydrochlorothiazide, if necessary, Olmesartan medoxomil tablets high dose, VKA-Based Regimen.
Related
- olmesartan/amlodipine + hydrochlorothiazide, if necessary. · Cardiovascular
- olmesartan medoxomil + hydrochlorothiazide, if necessary · Cardiovascular
- Olmesartan medoxomil tablets low dose · Cardiovascular
- Perindopril + amlodipine + if necessary, hydrochlorothiazide · Cardiovascular
- Sector hub: All tracked pharma companies